文献速递浆细胞疾病造血干细胞移植与细胞治疗

NY-ESO-1 SPEAR T细胞联合自体干细胞移植治疗骨髓瘤的长期安全性与活性

Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
PubMed 文献 · Blood Adv · 2019-01-01

本研究纳入25例HLA-A*02:01阳性且表达NY-ESO-1和/或LAGE-1的复发、难治或高危多发性骨髓瘤患者,在清髓性自体干细胞移植后输注最多1×10^10 NY-ESO-1 SPEAR T细胞。第42天客观缓解率为80%(95%CI 0.59-0.93),1年时为44%(95%CI 0.24-0.65);中位无进展生存期13.5个月,中位总生存期35.1个月。输注耐受良好,未报告细胞因子释放综合征,无致死性严重不良事件。

要点

  • ASCT后输注NY-ESO-1 SPEAR T细胞,第42天ORR 80%,1年ORR 44%。
  • 中位PFS 13.5个月,中位OS 35.1个月;3例在38.6-60.6个月仍无进展。
  • 未报告CRS,无致死性严重不良事件;T细胞在体内扩增、迁移至骨髓并持续存在。

核心结论

  • 在复发、难治或高危多发性骨髓瘤患者中,ASCT背景下输注NY-ESO-1 SPEAR T细胞与抗肿瘤活性相关。

研究设计与样本

  • 研究纳入25例HLA-A*02:01阳性且表达NY-ESO-1和/或LAGE-1的复发、难治或高危多发性骨髓瘤患者。
  • 采集T细胞后经激活、慢病毒转导NY-ESO-1c259TCR并扩增,清髓性ASCT后输注最多1×10^10 NY-ESO-1 SPEAR T细胞。

主要发现

  • 第42天客观缓解率80%(95%CI 0.59-0.93),第100天76%(95%CI 0.55-0.91),1年44%(95%CI 0.24-0.65)。
  • 1年时13/25例(52%)无疾病进展,其中11例为缓解者(1例严格完全缓解、1例完全缓解、8例非常好的部分缓解、1例部分缓解)。
  • 3例在输注后38.6、59.2和60.6个月仍无疾病进展。
  • 中位无进展生存期13.5个月(范围3.2-60.6个月),中位总生存期35.1个月(范围6.4-66.7个月)。
  • 输注耐受良好,未报告细胞因子释放综合征,研究期间无致死性严重不良事件;T细胞在体内扩增、迁移至骨髓、持续存在并表现肿瘤抗原导向功能。

关键数值与推荐

  • 客观缓解率采用国际骨髓瘤工作组(IMWG)共识标准评估。

临床怎么用

  • 对于HLA-A*02:01阳性且表达NY-ESO-1和/或LAGE-1的复发、难治或高危多发性骨髓瘤患者,ASCT后输注NY-ESO-1 SPEAR T细胞最多1×10^10显示抗肿瘤活性且耐受良好。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared by cancer antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and L-antigen family member 1 (LAGE-1) and presented by HLA-A*02:01. T cells collected from 25 HLA-A*02:01-positive patients with MM expressing NY-ESO-1 and/or LAGE-1 were activated, transduced with self-inactivating lentiviral vector encoding the NY-ESO-1c259TCR, and expanded in culture. After myeloablation and autologous stem cell transplant (ASCT), all 25 patients received an infusion of up to 1 × 1010 NY-ESO-1 specific peptide enhanced affinity receptor (SPEAR) T cells. Objective response rate (International Myeloma Working Group consensus criteria) was 80% at day 42 (95% confidence interval [CI], 0.59-0.93), 76% at day 100 (95% CI, 0.55-0.91), and 44% at 1 year (95% CI, 0.24-0.65). At year 1, 13/25 patients were disease progression-free (52%); 11 were responders (1 stringent complete response, 1 complete response, 8 very good partial response, 1 partial response). Three patients remained disease progression-free at 38.6, 59.2, and 60.6 months post-NY-ESO-1 SPEAR T-cell infusion. Median progression-free survival was 13.5 months (range, 3.2-60.6 months); median overall survival was 35.1 months (range, 6.4-66.7 months). Infusions were well tolerated; cytokine release syndrome was not reported. No fatal serious adverse events occurred during study conduct. NY-ESO-1 SPEAR T cells expanded in vivo, trafficked to bone marrow, demonstrated persistence, and exhibited tumor antigen-directed functionality. In this MM patient population, NY-ESO-1 SPEAR T-cell therapy in the context of ASCT was associated with antitumor activity. This trial was registered at www.clinicaltrials.gov as #NCT01352286.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stadtmauer EA, Faitg TH, Lowther DE, et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. 2019. PMID: 31289029. doi:10.1182/bloodadvances.2019000194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。